Acquired by EIP Pharma, Inc. in Oct 2023
Company logo

DFFN - Diffusion Pharmaceuticals Inc.

NASDAQ -> Healthcare -> Biotechnology
Charlottesville, United States
Type: Equity

DFFN price evolution
DFFN
(in millions $) 30 Jun 2023 31 Mar 2023 31 Jan 2023 30 Sep 2022
Current assets
Cash $15 $14.65 $10.11 $6.59
Short term investments $2.99 $12.41 $19.27
Net receivables
Inventory
Total current assets $15.69 $18.4 $22.64 $26.32
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments $2.99 $12.41 $19.27
Total assets $15.69 $18.4 $22.64 $26.32
Current liabilities
Accounts payable $0.93 $0.97 $1.13 $0.81
Deferred revenue
Short long term debt
Total current liabilities $1.46 $2.13 $2.42 $2.27
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $1.46 $2.13 $2.42 $2.27
Shareholders' equity
Retained earnings -$151.8 -$149.69 -$145.6 -$141.52
Other shareholder equity -$0 -$0.04 -$0.09
Total shareholder equity $14.23 $16.28 $20.22 $24.05
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $10.11 $37.31 $18.52 $14.18
Short term investments $12.41
Net receivables
Inventory
Total current assets $22.64 $37.82 $18.78 $14.65
Long term investments
Property, plant & equipment $0.3 $0.5
Goodwill & intangible assets $8.64 $8.64
Total noncurrent assets $0.02 $8.95 $9.46
Total investments $12.41
Total assets $22.64 $37.84 $27.73 $24.11
Current liabilities
Accounts payable $1.13 $0.95 $0.55 $1.25
Deferred revenue
Short long term debt $0.11 $0.11
Total current liabilities $2.42 $2.93 $2.44 $1.72
Long term debt $0.04 $0.14
Total noncurrent liabilities $0.48 $2.25
Total debt $0.15 $0.25
Total liabilities $2.42 $2.93 $2.92 $3.98
Shareholders' equity
Retained earnings -$145.6 -$130.01 -$105.91 -$91.72
Other shareholder equity -$0.04 $0
Total shareholder equity $20.22 $34.91 $24.81 $20.13
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $0.07 $1.31 $1.9 $0.8
Selling, general & administrative $2.22 $2.96 $2.34 $2.12
Total operating expenses $2.29 $4.27 $4.25 $2.92
Operating income -$2.29 -$4.27 -$4.25 -$2.92
Income from continuing operations
EBIT -$2.11 -$4.09 -$4.08 -$2.8
Income tax expense
Interest expense
Net income
Net income -$2.11 -$4.09 -$4.08 -$2.8
Income (for common shares) -$2.11 -$4.09 -$4.08 -$2.8
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $7.24 $8.5 $9.43 $6.62
Selling, general & administrative $8.74 $7.45 $6.44 $4.83
Total operating expenses $15.97 $24.68 $15.97 $11.55
Operating income -$15.97 -$24.68 -$15.97 -$11.55
Income from continuing operations
EBIT -$15.59 -$24.54 -$15.86 -$11.55
Income tax expense -$0.44 -$1.68 $0.33
Interest expense -$0.09
Net income
Net income -$15.59 -$24.1 -$14.19 -$11.8
Income (for common shares) -$15.59 -$24.1 -$16.14 -$11.8
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Net income -$2.11 -$4.09 -$4.08 -$2.8
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $0.06 $0.12 $0.19 $0.18
Total cash flows from operations -$2.65 -$4.97 -$3.47 -$2.76
Investing activities
Capital expenditures
Investments $3 $9.5 $7 $3.38
Total cash flows from investing $3 $9.5 $7 $3.38
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing
Effect of exchange rate
Change in cash and equivalents $0.35 $4.53 $3.53 $0.62
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$15.59 -$24.1 -$14.19 -$11.8
Operating activities
Depreciation $0.09 $0.1 $0.1
Business acquisitions & disposals
Stock-based compensation $0.93 $0.9 $0.74 $0.52
Total cash flows from operations -$14.97 -$14.5 -$13.55 -$9.86
Investing activities
Capital expenditures $0
Investments -$12.24
Total cash flows from investing -$12.24 $0
Financing activities
Dividends paid
Sale and purchase of stock $33.3 $18.87 $16.21
Net borrowings
Total cash flows from financing $0.01 $33.3 $17.89 $16.04
Effect of exchange rate
Change in cash and equivalents -$27.2 $18.8 $4.34 $6.19
Fundamentals
Market cap $18.87M
Enterprise value $3.87M
Shares outstanding 2.04M
Revenue $0.00
EBITDA -$13.08M
EBIT -$13.08M
Net Income -$13.08M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -1.44
EV/Sales N/A
EV/EBITDA -0.30
EV/EBIT -0.30
P/S ratio N/A
P/B ratio 1.33
Book/Share 6.97
Cash/Share 7.35
EPS -$6.41
ROA -62.99%
ROE -69.97%
Debt/Equity 0.12
Net debt/EBITDA 1.03
Current ratio 10.71
Quick ratio 10.71